Sk Biopharmaceuticals Co., Ltd. · KRX:326030
Sk Biopharmaceuticals — Q4 2024 Earnings Presentation
8 slides from Sk Biopharmaceuticals's earnings presentation, Feb 6, 2025
Slide 1: SK Biopharmaceuticals
SK Biopharmaceuticals 202414 427| 1 AZ Seay February 6, 2025 ° ~ \ ‘ \\ @) ‘Gore — -
Slide 2: Disclaimer
Disclaimer 2 ALE] 7/HE|O QE MEAS Sts AEA HS] A171 2(K-IFRS) Ol Chet Ah S| SEE OMA] Sli] BALE SHESIA| ES AEHOIAL EF SL EXT Of2{ HO] Holo} ofS FLOSS, BAt aol Al 144 LHSO| Oy Ao] HS S + Sect. ne me Wo job SMES SA AHO] SATS B7/ Het HaASS Agel Aolg, g. HAZUAl UMS HSS ASOHLt, HAS SefotA] SSUICH Gt, SAE |
Slide 3: • • • 1,630 • 1,340 1,366 • • • 1,293 1,052 1,133 909
• • • 1,630 • 1,340 1,366 338 233 288 • 491 231 • • 1,293 1,052 1,133 909 777 407 260 193 • 148 103 `23 Q4 `24 Q1 `24 Q2 `24 Q3 `24 Q4 2
Slide 4: FY2023 4Q23 FY2024 results
FY2023 FY2024 Q/Q Y/Y 연간 Y/Y 4Q23 1Q24 2Q24 3Q24 4Q24 1,268 3,549 1,140 1,340 1,366 1,630 5,476 +19.3% +28.6% 54.3% 777 2,708 909 1,052 1,133 1,293 4,387 +14.1% +66.3% +62.0% ($58.9M) ($207.4M) ($68.4M) ($76.9M) ($83.4M) ($92.9M) ($321.6M) (+11.4%) (+57.6%) (+55.1%) 53 116 82 51 131 5 269 -95.8% -89
Slide 5: XCOPRI US
XCOPRI US • • 1,293 35,516 1,133 1,052 26,283 909 26,059 777 757 17,765 17,567 634 539 498 474 10,518 403 317 279 188199 116 77 Source: SK LSI, Bloomberg, IQVIA¹ Source: SK LSI 12 32 1월 2월 3월 4월 5월 6월 7월 8월 9월 10월 11월 12월 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 2022 202
Slide 6: Pipeline
Pipeline • • Compound Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3 NDA Marketed Epilepsy : POS ¹ Epilepsy : POS (아시아 확장) Cenobamate Epilepsy : PGTC ² Epilepsy : POS (소아 연령 확장) Solriamfetol (L/O to Axsome) Small molecule Sleep Disorders Carisbamate Lennox-Gastaut Syndrome SKL24741 Epilep
Slide 7: Financial Story - New Modalities
Financial Story - New Modalities • • Modality Trends RPT TPD • • • • • • 1) '22-`28E WW Rx Sales %CAGR 2) '28E # of Marketed Product 6
Slide 8: Slide 8
SK Biopharmaceuticals — Q4 2024 Earnings Presentation on 6ix